Diabetes as a Cause of Clinically Significant Functional Cobalamin Deficiency

Lawrence R. Solomon, MD

OBJECTIVE—Functional cobalamin (Cbl) deficiency (i.e., high methylmalonic acid [MMA] values despite normal serum Cbl levels) is common in the elderly and associated with neuropathy and anemia. Because diabetes is also common in the elderly and diabetic neuropathy resembles that of Cbl deficiency, the role of diabetes in functional Cbl deficiency was explored.

RESEARCH DESIGN AND METHODS—A retrospective review was performed of all ambulatory community-dwelling adults with normal renal function evaluated for Cbl deficiency over a 12-year period in a primary care setting. Functional Cbl deficiency was defined as MMA values >250 nmol/L with Cbl levels >400 pg/mL.

RESULTS—In nondiabetic subjects, MMA values varied directly with age and inversely with serum Cbl. In diabetic subjects, MMA values also increased with age but did not fall as Cbl levels increased. Thus, when Cbl levels were >400 pg/mL, mean MMA values and the incidence of functional Cbl deficiency were both significantly greater in elderly diabetic subjects (at least 70 years old) than in elderly nondiabetic subjects. Moreover, neuropathy was present in 62% of diabetic subjects with high MMA values and in only 18% of diabetic subjects with normal MMA values. Finally, pharmacologic doses of Cbl improved MMA values and neuropathy in 88 and 86% of evaluable diabetic subjects, respectively.

CONCLUSIONS—These observations suggest that functional Cbl deficiency is common in elderly diabetic individuals, is associated with neuropathy, and is responsive to Cbl therapy. A role for oxidative stress in the pathogenesis of functional Cbl deficiency is proposed.

Cobalamin (Cbl) deficiency is common in elderly subjects who may have nonspecific neurologic complaints or appear clinically normal (1). Elevated levels of the Cbl-dependent metabolites, methylnalonic acid (MMA) and total homocysteine (tHcy), in asymptomatic patients with low or low-normal serum Cbl levels has been termed “subtle” or “preclinical” Cbl deficiency, suggesting a continuum of Cbl depletion beginning with decreased vitamin stores leading to metabolite accumulation and, finally, to clinical disease (2). However, 7–30% of diverse elderly populations have “functional” Cbl deficiency, defined by elevated metabolite values despite Cbl levels well within the normal reference range, and this disorder has been linked to decreased cognitive function, anemia, and neuropathy (3–9).

Functional Cbl deficiency might also result from a disorder common in the elderly. Diabetes is a particularly attractive candidate in this regard because it is associated with sensory and autonomic neuropathies similar to those seen in Cbl deficiency. Moreover, increased tHcy levels have been linked to diabetic neuropathy, and pharmacologic doses of Cbl alone combined with other vitamins may improve peripheral and autonomic nerve function in diabetic humans (3,10).

More recently, a 10-year retrospective review of symptomatic ambulatory subjects evaluated for Cbl deficiency found 9 of the 30 patients who had neurologic improvement with Cbl therapy had diabetes (30%) and 8 of these 9 individuals (88%) had functional Cbl deficiency (11). Thus, the roles of diabetes and patient age in functional Cbl deficiency were both evaluated in the total population (both symptomatic and asymptomatic) screened during this period and in the 2 years following.

RESEARCH DESIGN AND METHODS

Laboratory methods

Because tHcy levels increase in many settings, MMA was used as a more specific index of Cbl deficiency (3). Serum Cbl and MMA were measured as previously described (normal reference ranges: 200–1,100 pg/mL and 90–250 nmol/L, respectively) (11). When MMA and Cbl were measured on more than one occasion within a 4-week period without a change in treatment, the average values were used for analysis. Functional Cbl deficiency was defined as MMA levels >250 nmol/L when serum Cbl values were >400 pg/mL.

Patients

A retrospective review of the medical records of all ambulatory community-dwelling patients evaluated for Cbl deficiency between 1 August 1993 and 30 June 2005 was conducted as previously described (11). In a preliminary analysis of nondiabetic subjects with Cbl values >400 pg/mL, the geometric mean MMA value in subjects aged <60 years old (173 pg/mL) was similar to that in those aged 60–69 years (187 pg/mL) but was significantly lower than that in subjects at least 70 years old (225 pg/mL; P < 0.002). Thus, subjects were divided into those aged <70 years and those at least 70 years old. Because MMA values increase in renal insufficiency, individuals with serum creatinine values >1.4 mg/dL were excluded from analysis (3). For a brief period, normal MMA values were reported as “less than 400 nmol/L” and these patients were also excluded from analysis (n = 19).

Concurrent Cbl and MMA values were obtained in 370 individuals on 432

From the Section of Palliative Care, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.

Corresponding author: Lawrence R. Solomon, lawrence.solomon@yale.edu.

Received 3 January 2011 and accepted 16 February 2011.

DOI: 10.2337/dc11-0009

© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

care.diabetesjournals.org

Copyright American Diabetes Association, Inc., 2011

Diabetes Care 2011;34:1-5
occasions, including 47 individuals with type 2 diabetes evaluated on 59 occasions, and 54 patients who were not receiving Cbl therapy evaluated on more than one occasion at least 1 year apart. Patients were considered to have diabetes if they were receiving treatment with hypoglycemic agents or if they had a fasting blood glucose level >125 mg/dL or an HbA1c level >6.4%.

Treatments of diabetic patients included diet alone in 14 (30%), insulin in 11 (23%), a sulfonylurea in 15 (32%), a thiazolidinedione in 4 (9%), and metformin in 9 (19%), with more than one agent used in 6 subjects (13%). This study conforms to the principles of the Declaration of Helsinki of 1975 as revised in 2008, and the institutional human investigation committee determined that further review was not required.

Cbl treatment
Patients were treated with cyanocobalamin (2 mg/day orally or 1 mg i.m.) three times a week for 2 weeks, weekly for 8 weeks, and monthly thereafter, and were reevaluated within 1 to 3 months. Because of the intra-individual variability of metabolite levels in this population, decreases of MMA were considered significant if they were >116 nmol/L (i.e., >1 SD above the mean intra-individual variability of MMA) or between 64 and 116 nmol/L (i.e., between the mean and 1 SD above the mean intra-individual variability of MMA) to a value of <251 nmol/L (11). Neurologic improvement was considered to be significant if paresthesias completely resolved, observed ataxic gait became normal, and/or vibratory sensation that was completely absent, at least in the ankles, before therapy became easily detectable within 6 months of treatment.

Statistical methods
Population studies suggest skewed distributions for Cbl, MMA, and creatinine (12). Thus, geometric means, two-tailed Student t tests using log-transformed data, χ² values, and Spearman correlation coefficients were determined using StatPlus:mac 5.7 software (AnalystSoft, Vancouver, BC, Canada).

RESULTS

Effects of age and diabetes status on MMA values
Older individuals with Cbl values >400 pg/mL had mean MMA values that were 51 and 26% higher than their younger counterparts in diabetic and nondiabetic populations, respectively (Table 1). The incidence of functional Cbl deficiency was also greater in older than in younger individuals within the diabetic (8 of 11 [73%] vs. 6 of 17 subjects [35%]) and nondiabetic (19 of 47 [40%] vs. 17 of 73 subjects [23%]) populations (P ≤ 0.05).

Diabetic subjects with Cbl levels >400 pg/mL had higher mean MMA values than nondiabetic subjects in both age-groups, and this difference was statistically significant in the older population (Table 1). However, mean values for Cbl and creatinine were not significantly different in diabetic and nondiabetic subjects of comparable age. Functional Cbl deficiency was present in 8 of 11 older diabetic subjects (73%) compared with 19 of 47 younger diabetic subjects (40%; P < 0.05).

Determinants of MMA in diabetic and nondiabetic subjects
Age was a significant determinant of MMA in both diabetic and nondiabetic populations (Table 2). The relationship between age and MMA was particularly strong when Cbl levels exceeded 400 pg/mL (diabetes: r = +0.52, P < 0.006, n = 28; nondiabetes: r = +0.30, P < 0.001, n = 120). Cbl was a significant determinant of MMA only in nondiabetic subjects, but creatinine was not a significant determinant of MMA in either population.

Effect of Cbl therapy on MMA values
MMA responses to Cbl therapy were evaluable in 24 of 29 diabetic patients (83%) and in 110 of 173 nondiabetic patients (64%) with MMA values >250 nmol/L. Of these 134 patients, 77 received parenteral therapy (57%). Metabolic responses to Cbl therapy occurred in 115 of 134 patients (86%) overall (Table 3). MMA values fell into the normal range in 110 patients (81%). The response rate was not affected by diabetes status, patient age, or serum Cbl level (Table 3).

An additional eight diabetic subjects with renal insufficiency and high MMA values, despite normal serum Cbl levels, received Cbl therapy, including seven with creatinine values of 1.7 to 2.3 mg/dL and one individual receiving chronic hemodialysis with a creatinine value of 9.4 mg/dL. MMA values decreased significantly in five patients (63%) and returned to a normal value in three (38%; data not shown).

Neuropathy in diabetic subjects and the effects of Cbl therapy
Of the 47 diabetic subjects, 17 had no neurologic findings, 15 had neuropathy

Table 1—Effect of diabetes status relative to patient age on mean MMA values in subjects with Cbl levels >400 pg/mL.

| Variable       | Age <70 years | Age at least 70 years |
|---------------|---------------|-----------------------|
|               | Diabetic      | Nondiabetic           | Diabetic     | Nondiabetic           |
| MMA (nmol/L)  | 209           | 178                   | NS          | 315*                |
| Creatinine (mg/dL) | 1.0         | 0.9                   | NS          | 1.1                 |
| Cbl (pg/mL)   | 537           | 563                   | NS          | 622                 |
| Age (years)   | 54            | 48                    | NS          | 76                  |

Values are geometric means for the number of subjects and P values compare individuals with and without diabetes in the same age-group. NS, not significant. *P < 0.05 compared with diabetic subjects aged <70 years old. †P < 0.0025 compared with nondiabetic subjects aged <70 years old.

Table 2—Determinants of MMA in diabetic and nondiabetic populations

| Determinant | Diabetic (n = 57)* | Nondiabetic (n = 369)+ |
|------------|-------------------|-----------------------|
| Cbl (pg/mL)| +0.03             | NS                    |
| Age (years)| +0.38             | <0.005                |
| Creatinine (mg/dL) | +0.07           | NS                    |

Spearman correlation coefficients were determined as described in the RESEARCH DESIGN AND METHODS. *Omits two diabetes outliers with MMA values of 1,309 and 1,829 nmol/L. †Omits four nondiabetic outliers with MMA values of 1,319, 3,279, 1,928, and 4,911 nmol/L.
that was unexplained except for the presence of diabetes, and 15 had neuropathy that was possibly multifactorial. When the latter group was excluded from analysis, 21 of the remaining 32 patients had high MMA values (63%), and 13 of these patients had neuropathy (62%). In contrast, only 2 of the 11 patients (18%) with normal MMA values had neurologic signs or symptoms (P < 0.02).

At least 3 months of Cbl treatment was given to 14 diabetic subjects with neuropathy and increased MMA values, and significant responses were noted in 9 of 10 subjects (90%) with otherwise unexplained neuropathy and in 3 of 4 (75%) with multifactorial neuropathy, for an overall response rate of 86% (Table 4). Pretreatment Cbl levels were within the normal range in all 14 subjects and were >400 pg/mL in 9 subjects, including 8 of the 12 responders (75%). One evaluable subject with neuropathy received metformin (patient 13, Table 4).

**CONCLUSIONS**—Despite associations of high tHCy values with diabetic neuropathy and reports of clinical responses of diabetic neuropathy to Cbl therapy, the role of diabetes as a possible cause of functional Cbl deficiency has not been evaluated (3,13–16). Indeed, only three studies have reported MMA values in diabetic subjects, and these were limited by the lack of an age-matched control group, the presence of renal failure, or a focus on frank diet-related Cbl deficiency (3,17).

The current study confirms the association between age and functional Cbl deficiency in nondiabetic subjects and extends this observation to the diabetic population (Tables 1 and 2). Moreover, elderly diabetic patients with Cbl values >400 pg/mL had higher mean MMA values than both younger diabetic individuals and elderly nondiabetic individuals, suggesting an additive effect of diabetes and age on the risk of functional Cbl deficiency (Table 1). Differences between individuals with and without diabetes were not explained by differences in Cbl, age, or creatinine level, and pharmacologic doses of Cbl consistently decreased MMA values in all groups (Tables 1 and 3).

The clinical significance of functional Cbl deficiency is controversial. Associations with cognitive dysfunction, anemia, and neuropathy have been reported, and clinical responses to Cbl therapy have been noted (3,6,11,18). In contrast, clinical responses were not seen in six therapeutic trials (3,19–21). The current study indeed suggests that functional Cbl deficiency in diabetic subjects is clinically significant because neuropathy was more common when MMA values were high, and Cbl therapy improved neuropathy in 86% of evaluable patients (Table 4). Similar neurologic responses to Cbl therapy in diabetic subjects have been previously reported, but measures of Cbl and MMA were not obtained (3,10).

The mechanism of functional Cbl deficiency in diabetes and aging is unknown. Interestingly, functional Cbl deficiency in some inborn errors of Cbl metabolism results from the impaired reduction of Cbl from the CoIII transport form to the active Co or CoII coenzyme states, and correction of metabolic and clinical abnormalities in these disorders requires extremely high doses of parenteral Cbl (13). Moreover, Cbl is particularly susceptible to oxidation, and enzymatic reduction is also required for the decyanation of therapeutic cyanoCoIII/Cbl (14–16).

Because aging and diabetes are both associated with increased oxidative stress, a role for oxidative stress in the pathogenesis of functional Cbl deficiency and for the requirement of pharmacologic doses of Cbl in this setting is proposed (Fig. 1) (22–24). This hypothesis also implies that treatment with a reduced form of Cbl (e.g., methylcobalamin) may have an advantage over the oxidized forms of Cbl that are usually administered (i.e., cyanocobalamin and hydroxycobalamin).

Indeed, high doses of methylcobalamin have been reported to improve diabetic neuropathy, but the relationship of these responses to functional Cbl deficiency has not been studied (3,25).
Diabetes and functional cobalamin deficiency

Figure 1—Oxidative stress as a mediator of functional Cbl deficiency. AGE, advanced glycation end products; Epo, erythropoietin; GSH, reduced glutathione; NF-kB, nuclear factor-κB; ROS, reactive oxygen species.

This study is the first to report MMA values in diabetic subjects with normal Cbl levels and provide information on the Cbl responsiveness of neuropathy in relation to the presence of functional Cbl deficiency. Future studies of larger numbers of subjects with randomized, placebo-controlled trials of Cbl therapy are required to confirm and extend these observations.

Acknowledgments—No potential conflicts of interest relevant to this article were reported.

L.R.S. designed the research, analyzed data, and prepared the manuscript.

This study was presented in abstract and poster form at the 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 2005.

The author thanks D. Bonke for his suggestions regarding the possible impact of oxidative pathways on Cbl, and R. Green for his suggestion regarding the potential therapeutic use of methylcobalamin.

References
1. Stabler SP, Allen RH. Vitamin B12 deficiency as a worldwide problem. Annu Rev Nutr 2004;24:299–326
2. Carmel R. Current concepts in cobalamin deficiency. Annu Rev Med 2000;51:357–373
3. Solomon LR. Disorders of cobalamin (vitamin B12) metabolism: emerging concepts in pathophysiology, diagnosis and treatment. Blood Rev 2007;21:113–130
4. Tangney CC, Tang Y, Evans DA, Morris MC. Biochemical indicators of vitamin B12 and folate insufficiency and cognitive decline. Neurology 2009;72:361–367
5. Nardin RA, Amuck ANH, Raynor EM. Vitamin B(12) and methylocrylic acid levels in patients presenting with polyneuropathy. Muscle Nerve 2007;36:532–535
6. Turner MR, Talbot K. Functional vitamin B12 deficiency. Pract Neurol 2009;9:37–41
7. Lorenzi S, Vogesen M, Muller-Schumb S, Pflister HW. Clinically and MRI documented funicular myelosis in a patient with metabolical vitamin B12 deficiency but normal vitamin B12 serum level. J Neurol 2003;250:1010–1011
8. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry 2001;16:609–614
9. Eussen SJ, de Groot LC, Joosten LW, et al. Effect of oral vitamin B-12 with or without folate on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr 2006;84:361–370
10. Kregel KC, Zhang HJ. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol 2007,292.R18–R36
11. Makowski J, Fowler B, Kuhlmann MK. Disturbed homocysteine and methine cycle intermediates S-adenosylhomocysteine and S-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes. Clin Chem 2005;51:891–897
12. Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry 2001;16:609–614
13. Soliman LR. Disorders of cobalamin (vitamin B12) metabolism: emerging concepts in pathophysiology, diagnosis and treatment. Blood Rev 2007;21:113–130
14. Williams JHH. A novel role for vitamin B(12): cobalamins are intracellular anti-oxidants in vitro. Free Radic Biol Med 2009;47:184–188
15. Kim J, Gherasim C, Banerjee R. Decaying and reactive oxygen species.